

SUPPLEMENTARY TABLES

Supplementary Table 1. The correlation between TFAP2A expression and infiltrating immune cells in ACC, CHOL, DLBC, ESCA, GBM, HNSC, LUAD, LUSC, OV, PAAD, SKCM, THCA, UCEC, UVM.

	ACC	CHOL	DLBC	ESCA	GBM	HNSC	LUAD	LUSC	OV	PAAD	SKCM	THCA	UCEC	UVM
aDC	-0.0119	0.0311	0.076	-0.0429	-0.2658***	0.1248**	0.1132**	-0.1847***	0.1571**	-0.0249	-0.2668***	0.1249**	0.0103	-0.3809***
B cells	-0.1997	-0.1109	-0.1792	-0.3292***	-0.0836	-0.1491***	-0.1241**	-0.3088***	0.1075*	-0.2144**	-0.1579***	0.1317**	-0.0686	-0.2074
CD8 T cells	-0.3361**	-0.2129	-0.2765	-0.2376**	0.0499	-0.0894*	-0.125**	-0.2204***	0.1387**	-0.2137**	-0.096*	0.1965***	-0.0891*	-0.002
Cytotoxic cells	-0.2947**	-0.2311	-0.1711	-0.0456	-0.2981***	-0.1564***	-0.0685	-0.3204***	0.1611**	-0.291***	-0.2006***	0.0771	-0.2009***	-0.3821***
DC	-0.2205	-0.1367	0.0129*	-0.1264	-0.2132**	-0.16***	-0.172***	-0.2476***	0.1614**	-0.195**	-0.1626***	0.1437**	-0.1017*	-0.1835
Eosinophils	-0.157	-0.512**	-0.2054	-0.5642***	-0.1447	0.0128	-0.1992***	-0.3001***	0.0172	-0.3718***	-0.1179*	0.3074***	-0.0648	-0.2331*
iDC	-0.2167	-0.0093	-0.1399	-0.0392	-0.187*	-0.1435**	-0.1737***	-0.3792***	0.0715	-0.2377**	-0.3453***	0.185***	-0.0881*	-0.2789*
Macrophages	-0.227*	-0.0193	-0.0486*	-0.0386	-0.2506**	-0.119**	-0.0855*	-0.3176***	0.0575	-0.0766	-0.3864***	0.1079*	-0.0583	-0.4255***
Mast cells	-0.1284	-0.0955	0.045*	-0.2941***	-0.0718	-0.1265**	-0.2024***	-0.3157***	0.0277	-0.3485***	-0.2279***	0.1346**	-0.0255	-0.3164**
Neutrophils	-0.1552	0.0414	0.0062**	-0.2031**	-0.1833*	0.093*	-0.0236	-0.1975***	0.146**	-0.1496*	-0.2375***	0.0678	0.0408	-0.3409**
NK														
CD56bright cells	-0.3455**	0.0324	-0.0601	-0.3471***	-0.1915*	-0.2606***	0.0275	0.0136	0.053	0.2771***	-0.1525***	0.0753	-0.0977*	-0.2395*
NK														
CD56dim cells	-0.092	-0.1115	0.1701	0.25**	-0.2563***	0.0227	0.1073*	-0.1439**	0.1732***	-0.0856	-0.3123***	0.0948*	-0.1049*	-0.4691***
NK cells	-0.0647	0.4293**	0.0084**	0.1271	-0.2709***	-0.1462**	0.079	0.0708	-0.0414	-0.1085	-0.1512**	0.0165	0.009	-0.204
pDC	-0.2412*	-0.3959*	-0.0856	-0.514***	0.0094	-0.3327***	-0.1099*	-0.1987***	0.0461	-0.3113***	-0.3251***	0.0817	-0.122**	-0.2523*
T cells	-0.2983**	-0.1876	-0.1779	-0.2887***	-0.2323**	-0.1025*	-0.0766	-0.3223***	0.1656**	-0.322***	-0.2327***	0.1255**	-0.1476***	-0.4195***
T helper cells	0.025	-0.2633	-0.0424*	-0.16*	-0.1086	0.1407**	-0.0194	-0.1176**	0.1232*	-0.0956	-0.2449***	0.2024***	-0.0034	-0.1389
Tcm	0.0653	-0.2232	-0.1659	0.402***	0.1082	0.2179***	-0.0571	0.0592	0.1172*	-0.084	-0.1351**	0.1837***	0.1377**	0.0207
Tem	-0.0886	-0.1104	-0.1344	-0.5188***	0.0941	-0.1586***	-0.1342**	-0.1038*	0.1313*	-0.1389	-0.0322	0.0322	-0.0873*	-0.1192
TFH	-0.211	-0.0165	-0.2302	-0.174*	0.0984	-0.0307	-0.1301**	-0.2556***	0.0294	-0.349***	-0.3006***	0.2019***	-0.0548	-0.3773***
Tgd	-0.0889	-0.0082	0.0038**	0.0793	0.0311	0.1851***	0.0317	-0.2336***	-0.1038*	-0.1999**	-0.2453***	0.1336**	-0.0131	-0.5756***
Th1 cells	-0.11	-0.0206	0.0319*	-0.0735	-0.0521	0.1011*	-0.0253	-0.2637***	0.1208*	-0.0619	-0.341***	0.2395***	-0.1164**	-0.5636***
Th17 cells	-0.0772	-0.2342	-0.0299*	-0.5629***	-0.1172	0.0138	-0.0981*	-0.1642***	0.1109*	-0.2741***	-0.1342**	0.0729	-0.0152	0.3918***
Th2 cells	0.3564**	0.0625	-0.0725	0.1119	0.118	0.1258*	0.2262***	-0.1154**	0.0834	0.2516***	-0.1307**	0.1733***	0.1428***	-0.5833***

(Spearman correlation coefficient and P-Value, *p < 0.05, **p < 0.01, and ***p < 0.001.)

Supplementary Table 2. Sequence of primers.

Primer name	Sequence
TFAP2A-F	GACCTCTCGATCCACTCCTTAC
TFAP2A-R	GAGACGGCATTGCTGTTGGACT
PD-L1-F	TGCCGACTACAAGCGAATTACTG
PD-L1-R	CTGCTTGTCCAGATGACTTCGG
GAPDH-F	CGGAGTCAACGGATTGGTCGTAT
GAPDH-R	AGCCTTCTCCATGGTGGTGAAGAC
IDO1-F	GCCTGATCTCATAGAGTCTGGC
IDO1-R	TGCATCCCAGAACTAGACGTGC
LAG3-F	GCAGTGTACTTCACAGAGCTGTC
LAG3-R	AAGCCAAGGCTCCAGTCACCA
IL12A-F	TGCCTTCACCACTCCAAAACC
IL12A-R	CAATCTCTCAGAAGTGCAAGGG
CCL5-F	ACACACTTGGCGGTTCTTCGG
CCL5-R	CCTGCTGCTTGCTACATTGC
PRF1-F	ACTCACAGGCAGCCAACTTGC
PRF1-R	CTCTGAAGTCAGGGTGCAGCG
ICAM1-F	AGCGGCTGACGTGTGCAGTAAT
ICAM1-R	TCTGAGACCTCTGGCTTCGTCA

Supplementary Table 3. The sequences of five PD-L1 promoter region and predicted binding sites.

Site	Sequences
P1 (-2400 to +100 bp)	ATGACTCACCTGAGGACAATGTTAAAATGTTGACCTCCAAGGCCCTGCCCAAGTTGGATCCCAGGCAGAACCCCTGGA ATCTGTATTAAACATTAACCCCAAGTCGAGTGTAAATGCAAGTAACCCTCAGAGACACTCTGAGAAAACAGCACATTGGCA ATGATGAATTATATGCTAAAATGAATAGAGTAGATGTTACATGAATAGGAAGTGGTGTATTCAAGATGACCATACTGATC TAGCTCTCAGCCCTGGCTCCCCACTGCTCTCTCCCATCTCAGCACTCTCCATCTATTCTGCAAAATAAAAATTCTC CAGAGTTCAAGGACTTAACCCCCACTCATTAACCATCTGTTGTTACATATTCTGAGGTAATAAAAATTCTCTTT CTAACACAGCCTGTTCAATCTCGGGTAGTTGATCAATGTTATGGGAAAATGAATGGCTGAAGGGTAGAAAACAGGTG GGAAAAGATGAACAAAAACGAATCCTCAGATTACTAATACGCAAATCAGCAGCAGCAAGCTGAGCAAAATACCCCTAAT TCCCCTCAGCAACTTAGAGAAAAGGAAATTCCGTTGCCTATTGATCATTAGTAGGTTAGACCTGAGGAAACACTGCTTCAAAA ACAAAAACAAAATACCCATCCCCAGTTAAAAAATTATTGATCATAGATCATCCAGGCCATCTAGGAGGATATGATTAATCTG GCTACTTGGTAAATTATTGCCAAGTTAACTCAGCTAGTTAGTGTAGATGGCTCTGAAGCCAGTTTTTTGTTTG TTTTTGAGACCTCAAGAGTCATGTAAGTCAAGAGTCAAGAGTCAAGAGTCAAGAGTCAAGAGTCAAGAGTCAAGAGTCAAG AAACATTAAATGAAAATATCAGAGGCATTGAGATAGTAGATCTAAGTATTGATGAACTTGTGACATGTTGTTG CATACACAGACTATATATGCACTGTTGAAACTGTTGAGGAAAGTCACCCAAACTACAGTCACCAAAATTGCTTACTATG AGTTGGGAAGTCACCCAACTTCGGGAACCTTGGGAAAGTCACCCAAACTACAGTCACCAAAATTGCTTACTATG GACCTCAAAGTGATTGAAAGAAGGAACATCTGAGCTGGCCCAAACCCATTGCAATTATTGGGCCAAAGAGAAC TCCATGCTCCTGCCAATCAAGGCAGTGTCAAGCCTCAATAATTCCAGATAAAAATAAAATCTGATACAATCAGAAC TGAAAATTCTTATTGAGGAAAGCAATGTCATAACCAATGCAAGGGCTATCTCAATTCTCATTGAGTATTGACT GCAGTTGAAATGAATAAGAAGGAAAGGCAACACAGAAGAGTCAATTCTCAATTGAGGAAAGGAGAAAAGGAGAAA AGGGAGCACACAGCAGGTGGCTCAAGCCTGTAATATCAGCAGCTTGGCGATCACTTGAGGTCAGGAGTTGAGAGAAA AGAGAGCACCTAGAAGTTCAGCGCGGATAATACTTAAGTAAATTGACACCCTGCTCATTTGGGCCATTCACTA ACCCAAAGCTTCAAAGGGCTTCTTAACCCCTACCTAGAATAGGCTTCCGAGCCTTAATCCTAGGGTGGCAGAATATC AGGGACCTGAGCATTCTTAAAGATGTTAGCTGGGATGGGAGTTCTTAAATGACAAGCAAAGCAATGAGTTTCTTATTG CGAGGAACCTTGAGGAAGTCACAGAAATCCACGATTAAAATATATTCTCATTATAACACACACACACACAC ACTTTCTAGAATAAAAACCAAAGCCATGGTCTGCTGACTTTTATATGTTAGAGTTATCAAGTTATGTCAGA TGGTCAGTCACCTTGAAGAGGCTTATCAGAAAGGGGAGCCTTCTGATAAAGGTTAAGGGTAACCTTAAGCTCTT CCCCCTGAGGTAATCAAGGTGGCTTCAAGTGTGGCTTGTGAAATTCTTCTTATTAAATAACACTAAATGTT ATTGCTTAAATCTCGAAACTCTCCGGTGAATACTCATTACAAGAAAAGTGGACTGACATGTTCACTTCTGTTCA TTCTATACACAGCTTATCTAGGACACCAACACTAGATAACCTAAAGTAAAGCTTCCGCCGATTTCACCGAAGGTCAG AAAGTCCAACGCCGAAACTGGATTGCTGCCCTGGCAGAGGTGGGGACCCGCCCTCCGGCTGGCGAAC CTGAGCAGCTGGCGCGTCCCGCGCGCCCCAGTTGCGCAGCTCCGAGGCTCCGACCAGGCCGCTCTGCGGCC TGAGGTAGGGAGCGTTCTCCGGGTGCCACGCCAGTATCTC GAACAAAAACACGAATCCTCACATTACTAATACGCAAATCAGCAGCAAGCTGAGCAAATACCCCTAATTCCCATCAG CAACTTGTAGAGAAAGGCAAATTCCGTTGCCTCATTGATCATTAGTAGACCTGTTCTAAACAAACAAA AAAATACCCATCCCCAGTTAAAAAATTATTGATCATAGATCATCCAGGCCATCTAGGAGGATATGATTAATCTGCTACTTGG TAAATTATTGCCAAGTTAACTCAGCTAGTTAGTGTAGATGGCTCTGAAGCCAGTTTTTTGTTTTGTTTTGCA GACCTCAAGAGTCATGTAAGTCACTGAGCAGATCATAAAGTTATGCCCTGGCTTGACCATTAGAAAATACAG ATGAAAATATCAGAGGGCATTGAGATAGTCAAGTATTCTCATGAAACTTGTGACATGTTGTCATACACAG ACTATATATATGCACTGTAACCTGTAACCTGATTGTCACATAATGCTTATATTCTCAGAGGTCAAGTCACCAAAAGTGGGAA GTCACCCAACTTCGGGAACCTTGGGAGTCACCCAAACTACAGTCACCAAAATTGCTTACTATGACCTCAAA AGTGAATTGAAAGAAGGAACATCTGAGCTGGGCCAAACCCATTGCAATTATTGGGCCAAAGAGAACCTCATGCTCC TGCCAAATCAAGGCAGTGTCAAGCCTCAATAATTCCAGATAAAAATACTGATACAATCAGAATGTTGAAATTCT TATTGAGGAAAGCAATGTCATAACCAATGCAAGGGCTATCTCAATTCTCATTATGAGTATTGAACTGCA TGAATAAGAAGGAAAGGCAAACACAGAAGAGTCAATTCTCAATTAGAAAAGAGAAAAAGGAGAAC ACAGGCACGGTGGCTCAAGCCTGTAATATCAGCACTTGGGGATCACTTGAGGTCAGGAGTTGAGAAAAGAGAAC CTAGAAGTTAGCGCGGATAATACTTAAGTAAATTGACACCCTGCTCATCTGGGCCATTCAACCCAAAGC TTTCAAAGGGCTTCTTAACCCCTACCTAGAATAGGCTTCCGAGCCTTAATCCTAGGGTGGCAGAATATCAGGGACCC GAGCATTCTTAAAGATGTTAGCTGGGATGGGAGTTCTTAAATGACAAGCAAATGAGTTCTTATTGTCAGGAAACT TTGAGGAAGTCACAGAAATCCACGATTAAAATATATTCTCATTATAACACACACACACACTTCTAGA ATAAAAACCAAAGCCATGGTCTGCTGACTTTTATATGTTAGAGTTATCAAGTTATGTCAGA CCTTGAAGAGGCTTTATCAGAAAGGGGAGCCTTCTGATAAAGGTTAAGGGTAACCTTAAGCTTACCCCTCTGAA GGTAAAATCAAGGTGGCTTCAAGTGTGGCTTGTGAAATTCTTCTTATTAAATAACACTAAATGTTGAGGAACT TCTCAGAAACTCTCCGGTGAATACTCATTACAAGAAAAGTGGACTGACATGTTCACTTCTGTTCTTATTCTATACA CAGCTTATTCTAGGACACCAACACTAGATACTTAAACTGAAAGCTCCGCCATTTCACCGAAGGTCAAGGAAAGTCAA CGCCCGCAAACACTGGATTGCTGCCCTGGCAGAGGTGGGGACCCGCCCTCCGGCTGGCGAACGCTGAGCAGC TGGCGCGTCCCGCGCGCCCCAGTTGCGCAGCTCCGAGGCTCCGACCAGGCCGCTCTGCGCCCTGCGAGGTAG GGAGCGTTGTTCTCCCGCGGGTGCCACGCCAGTATCTC ATATGCACTGTAAACTGTTGACCTATAATGCTTATATTCTTAGAGGTCACAGTCACCAAAAGTGGGAGTCACC CAACTCAGGAACTTGGGAGTCACCCAAACTACAGTCACCAAAATTGCTTATCTACTATGTCACCTCAAAAGTGTAT TTGAGGAAAGGAACATCTGAGCTGGCCCAAACCCATTGCAATTATTGGGCCAAAGAGAAACTCCATGCTCTGCCAA ATCAAGGCAGTGTCAAGCCTCAATAATTCCAGATAAAAATAAAATCTGATACAATCAGAATGTTGAAATTCTTATTG GGAAGCAAATGTCATAACCAATGCAAGGGCTATCTCAATTGATCATTGAGTATTGAACTGCAAGTGAATGAAATA AGAAGGAAAGGCAAACACAGAAGAGTCAATTCTCAATTAGAAAAGAGAAAAAGAGAAAAGGGAGCACACAGGC ACGGTGGCTCAAGCCTGTAATATCAGCACTTGGCGGATCACTTGAGGTCAGGAGTTGAGGAGAGGAGCAC GTTCAGCGCGGGATAATACTTAAGTAAATTGACACCCTGCTCATCTGGGCCATTCAACTAACCCAAAGCTTCAA
P2 (-1900 to +100 bp)	
P3 (-1400 to +100 bp)	

P4 (-900 to +100 bp)

AAGGGCTTCTTAACCCCTACCTAGAATAGGCTCCGCAGCCTTAATCCTAGGGTGGCAGAATATCAGGGACCCCTGAGCA
TTCTTAAAGATGTAGCTCGGGATGGGAAGTCTTTAATGACAAGCAAATGAAGTTCTTACCTAGGGTGGCAGAATATCAGGGACCCCTGAG
GAAGTCACAGAACGATTAAAATATTCTTAC
AACCAAAGCCATATGGCTGCTGACTTTATATGTTAGAGTTATATCAAGTTATGTCAGATGTCAGTCACCTG
AAGAGGCTTATCAGAAAAGGGGAGCCTTCTGATAAAGGTTAACCTAAGCTTACCTAGGGTGGCAGAATATCAGGGACCCCTGAG
AATCAAGGTGCGTTAGATGTTGGCTGTTAATTTTATAATAAC
GAAACTCTCCGGTAAAATCTCATTACAAGAAAAGTGACTGACATGTCAGTTCACCTCTGTTCACTTCTGTTCACTTCTGTT
TTATTCTTAGGACACCAACACTAGATACCTAAACTGAAAGCTCCGCCATTCCACCGAAGGTCAAGGAAAGTCCAACGCC
GGCAAACCTGGATTGCTGCCCTGGCAGAGGTGGCGGACCCCGCCTCCGGCCTGGCGAACGCTGAGCAGCTGGC
CGTCCCGCGGCCAGTTCTGCCAGCTCCGAGGCTCCGACCAGCCGCGCTCTGCCCTGCAGGTAGGGAGCAGCTGGTCTCCCG
GTGTTCTCCCGGGTCCCCACGGCCAGTATCTC

P5 (-400 to +100 bp)

CCTGAAATATCAGCACTTGGCGATCACTTGAGGTCAAGGAGTTGAGAAAAGAGACCTAGAAGTTCAGCGCGGA
TAATACTTAAGTAAATTATGACACCATCGTCTGTCATCTGGGCCATTCACTAACCCAAAGCTTCAAAGGGCTTCTTA
ACCCCTACCTAGAATAGGCTCCGCAGCCTTAATCCTAGGGTGGCAGAATATCAGGGACCCCTGAGCATTCTAAAAGATGT
AGCTCGGGATGGGAAGTCTTTAATGACAAGCAAATGAAGTTCTTACCTATGTCAGGAACTTGAGGAAGTCACAGAAATC
CACGATTTAAAATATATTCTTAC
GGGTCTGCTGACTTTATATGTTAGAGTTATCAAGTTATGTCAGATGTCAGTCACCTGAGAGGCTTATC
AGAAAGGGGAGCCTTCTGATAAAGGTTAACCTTAAGGTTAACCTTAAGCTTACCCCTGAGGTAAGTAAAATCAAGGTGCG
TCAGATGTTGGCTGTTGAAATTCTTTTATAATAACACTAAATGTTGATTGCTTTAATCTCGAAACTCTCCCG
GTGAAAATCTCATTACAAGAAAAGTGACTGACATGTTCACTTCTGTTCACTTCTATACACAGCTTATTCTAGGACA
CCAACACTAGATACCTAAACTGAAAGCTCCGCCATTCCACCGAAGGTCAAGGAAAGTCCAACGCCGGAAACTGGATT
TGCTGCCCTGGCAGAGGTGGCGGACCCCGCCTGGCGAACGCTGAGCAGCTGGCGTCCCGCG
CCCAGTTCTCGCAGCTCCGAGGCTCCGACCAGCCGCGCTCTGCCCTGCAGGTAGGGAGCAGCTGGTCTCCCG
GGGTGCCACGCCAGTATCTC

Site	Sequences
-2354 to -2343 bp	TGCCCGCAAGTT
-2301 to -2290 bp	AACCCCAAGTCG
-2165 to -2137 bp	GCCCTGGCT
-1930 to -1919 bp	TGGCTGAAGGGT
-1530 to -1519 bp	TGCCCTGGGTCT
-1183 to -1175 bp	GCCAAAGAG
-923 to -912 bp	AGCACACAGGCA
-908 to -897 bp	TGGCTCAAGCCT
-766 to -756 bp	AACCCAAAGCT
-711 to -695 bp	GCCTTAATCCTTAGGGT
-498 to -490 bp	GCCATATGG
-371 to -361 bp	AACCTTAAGCT
-80 to -67 bp	GCTGCCTGGGCAG
54 to -33 bp	CCCCGCCTCCGGGCTGGCGCA
-13 to +4 bp	TCCCCGCGGCCAGTT
+14 to +24 bp	TTCCCGAGGCT
+47 to +58 bp	CGCCTGCAGGTA
+81 to +92 bp	TGCCACGCC